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A pproval of new therapies for ulcerative colitis (UC) has been informed by data from randomized controlled trials (RCTs). Since the first placebocontrolled RCT in UC over 60 years ago, 1 clinical trials have become larger and more sophisticated in their design. In recent years, treatment targets in UC have evolved, from symptom-based scoring assessments to normalization of objective measures of inflammation such as endoscopic appearance, biomarkers, and histology. 2 However, the U.S. Food and Drug Administration has continued to require inclusion of patient-reported outcomes (PROs) as clinical trial endpoints to accurately capture the patient's experience.
3 Assessment of safety endpoints has also evolved. As novel therapies are designed to target specific components of the immune response, treatment-specific short-and long-term adverse events (AEs) have been recognized, including the risk of opportunistic infections, malignancies, infusion or injection reactions, and the formation of antidrug antibodies.
Given the progress that has occurred in this field, it is surprising that no formalized consensus has been established regarding what to measure, how to measure, or when to measure efficacy and safety endpoints in UC trials. In response to this unmet need, we have proposed the collaborative development of a core outcome set (COS) for use in UC RCTs. 4 A COS is a consensus-derived minimum set of outcomes that should be measured and reported in all clinical trials of a given disease.
5 COS implementation reduces heterogeneity in outcome reporting and enhances quality of evidence synthesis in systematic reviews and meta-analyses.
Selection of outcomes for development of a COS is a multistep process, starting with a comprehensive review of existing endpoint definitions and measurement tools.
4,5 Accordingly, we systematically review the efficacy and safety outcomes reported in placebo-controlled UC trials. Specifically, we aim to explore the evolution of endpoint reporting in UC trials over time and characterize the key outcome domains of a conceptual framework for COS development.
Methods

Search Strategy
We searched MEDLINE (1948 MEDLINE ( -2017 , EMBASE (1947 EMBASE ( -2017 , and the Cochrane Central Register of Controlled Trials (1994 Trials ( -2017 , without language restrictions, from inception to March 1, 2017 . This was supplemented with hand-searches of conference proceedings from Digestive Disease Week and United European Gastroenterology Week (2012 Week ( -2016 . The key search terms identify RCTs (including concepts of blinding, randomization, and placebo control) in patients with UC. Key search terms were combined using Boolean operators (Supplementary Table 1 ).
Study Eligibility Criteria
Studies fulfilling the following inclusion criteria were eligible: (1) a placebo-controlled RCT in adult UC patients; (2) medical intervention with an aminosalicylate compound, corticosteroid, immunosuppressant, biological agent, or small molecule therapy; (3) use of the Mayo Clinic Score (MCS), 6 UC Clinical Disease Activity Index (UCDAI) (Supplementary Table 2) , 7 or modifications of these indices as enrollment criteria; and (4) duration of at least 2 weeks for induction and 4 months for maintenance trials. We excluded trials of probiotics, antibiotics, complementary therapy, or devices and trials of hospitalized patients with fulminant UC.
Data Extraction
Citations for potentially relevant studies were screened independently by 2 investigators (C.M., T.M.N). Disagreements were resolved by consensus. The primary data extraction included trial reporting of: (1) efficacy outcomes (including clinical or composite-clinical, endoscopic, histologic, biomarker, and PROs); and (2) safety outcomes (including occurrence of any AEs, serious AEs resulting in hospitalization, drug discontinuation, or persistent or clinically significant disability, deaths, and organ-specific AEs). Clinical-composite outcomes were defined by outcomes including both subjective reported symptoms and objective assessment (eg, sigmoidoscopy). PROs were defined by outcomes directly reported by the patient.
Data Synthesis and Analysis
A comprehensive inventory of efficacy and safety outcomes and definitions was generated. These were subsequently organized into outcome subdomains and summarized in tabular form. The proportion of studies reporting each outcome was calculated, and stratified by decade of publication (1987-1996, 1997-2006, 2007-2017) . The evolution of outcome reporting was summarized in matrix form with outcome domains listed in rows and frequency of outcome reporting plotted in grayscale gradient over a time axis. As this qualitative review evaluates outcome measures and definitions rather than measures of efficacy, assessment of study quality was not performed. Similarly, a funnel plot incorporating measures of precision and effect size is not appropriate for a qualitative review.
including patients from 68 induction and 15 maintenance trials (Supplementary  Table  3) . 13, 23, 36, 38, 41, 47, 51, 58, 65, [70] [71] [72] [73] [74] Characteristics of the included RCTs are summarized in Table 1 . In total, 17,737 patients participated with 33.4% of patients (5,918 of 17,737) randomized to placebo. Most trials were phase III studies (35 induction, 11 maintenance) and over two-thirds were published after 2006 (46 induction trials, 11 maintenance trials). A biological agent was the active comparator in 47.0% (39 of 83) of RCTs.
Clinical or Composite-Clinical Efficacy Outcomes and Definitions
Clinical response or improvement was reported in 83.8% (57 of 68) of induction trials [6] [7] [8] [9] [10] [11] [12] 14, 15, 17, 56, 58, 59, 62, [64] [65] [66] [67] [68] [69] and 73.3% (11 of 15) of maintenance trials (Table 2) . 23, 36, 38, 41, 47, 51, 58, 65, 71, 73 Clinical remission was reported in 91.2% (62 of 68) of induction trials 6, 9, [11] [12] [13] [14] [16] [17] [18] [19] [21] [22] [23] and 93.3% (14 of 15) of maintenance trials. 13, 23, 36, 38, 41, 47, 51, 58, 65, 70, [72] [73] [74] Combined clinical and endoscopic remission was used as a trial endpoint in 11 induction studies. [26] [27] [28] 37, 48, 55, 57, 60, 61, 63 In maintenance trials, 5 RCTs 13, [70] [71] [72] 74 reported clinical relapse or worsening as a study endpoint.
Over 50 different definitions of response or remission were used (Supplementary Table 4 ). The UCDAI was used as the assessment tool in 21 induction [7] [8] [9] 11, 12, 14, 15, 20, 22, 24, 25, [27] [28] [29] 35, 37, 42, 44, 48, 55 and 4 maintenance RCTs [70] [71] [72] 74 ; the MCS was used in 38 induction 6, 13, 16, 19, 23, 26, [30] [31] [32] [33] [34] 36, [38] [39] [40] [41] 43, [45] [46] [47] [49] [50] [51] [52] [53] [54] [56] [57] [58] [59] [60] [61] [62] [63] [64] [65] [66] [67] [68] [69] and 11 maintenance RCTs. 13, 23, 36, 38, 41, 47, 51, 58, 65, 73 Other tools for assessing clinical response or remission, including the Rachmilewitz Clinical Activity Index, 60,69 the modified Truelove and Witt's index, 20 and the Ulcerative Colitis Clinical Score 21 were uncommonly utilized. Studies published prior to 2003 defined response by absolute or relative changes in UCDAI-MCS compared with baseline or by improvements in the physician global assessment. 8, 10 This practice has evolved over time, whereby clinical response and remission being defined by a combination of change in MCS or UCDAI with specific subscore cutoffs. RCTs published after 2006 typically defined clinical response by a reduction in MCS of 3 and 30% compared with baseline, with rectal bleeding subscore reduction of 1 from baseline or absolute rectal bleeding subscore of 0 or 1. Remission was most commonly defined by MCS of 2 with no subscores >1. In maintenance trials, relapse has been conventionally defined by recurrence or increase in rectal bleeding or stool frequency. 
Endoscopic Efficacy Outcomes and Definitions
Fifty-seven (83.8%) induction 14, [16] [17] [18] 20, 21, and 12 (80.0%) maintenance trials 23, 36, 38, 41, 47, 51, 58, 65, 70, 73, 74 reported endoscopic outcomes but this varied by decade of publication: 96% of RCTs (55 of 57) published after 2006 described endoscopic outcomes (Figure 3 ). Most studies assessed mucosal appearance using the endoscopic subscore of the MCS-UCDAI, with mucosal appearance rated on a 4-point scale (Supplementary Table 5 ). Mucosal healing was typically defined as an MCS-UCDAI 1 and endoscopic response defined by a reduction in MCS-UCDAI subscore 1 from baseline. However, few authors used more stringent definitions of mucosal healing, based on MCS-UCDAI subscore of 0, 20, 30, 55 or modifications to the subscore whereby absence of friability was required for classifying mucosal healing. 27, 28, 42 Other endoscopic assessment indices, including the Baron score 16, 18 and UC Endoscopic Index of Severity 62 were infrequently used. Table 6 ). Eighteen (26.5%) induction 12, 14, 19, 21, 26, 32, 37, 38, 45, [48] [49] [50] 55, 59, 60, 64, 65, 67 and 2 (13.3%) maintenance studies 38,65 reported histologic response or remission outcomes. Multiple different scoring systems have been used to assess histologic endpoints, including the Riley or modified Riley Index, 14, 21, 50, 59, 67 Saverymuttu score, 37,48 and Robarts Histopathology Index. 67 The Geboes score was the most commonly used histology assessment tool in 8 induction 26, 38, 45, 49, 60, 64, 65, 67 and 2 maintenance trials.
Histologic Efficacy Outcomes and Definitions
38,65
Biomarker Outcomes and Definitions Biomarker outcomes were described in 18 (26.5%) induction 18, 25, 33, 34, 36, 39, 46, 49, 50, 52, 53, 56, 61, 62, 64, 65, 67, 69 and 2 (13.3%) maintenance trials. 41, 65 A greater proportion of studies published after 2006 (36.8%) identified either serum or fecal-based biomarkers as a treatment endpoint (Figure 3 ). Reductions in fecal calprotectin (FCP) 34, 39, 41, 49, 50, 52, 62, 64, 65, 67, 69 and serum C-reactive protein 18, 25, 33, 34, 36, 39, 46, 50, 52, 53, 56, 61, 62, 64, 65, 67, 69 were the most commonly reported biomarker outcomes.
PROs and Definitions
PROs were reported in 20 (29.4%) induction 18, 19, 21, 29, 30, 32, 36, 39, 41, 46, 47, 52, 56, 60, 61, 64, 66, 69 and 5 (33.3%) maintenance trials. 36, 41, 47, 65, 73 Most studies reporting PROs were published after 2006 (38.6%, 22 of 57 RCTs; Figures 2 and 3 ). Quality of life was frequently assessed using the Inflammatory Bowel Disease Questionnaire (IBDQ) with a positive response defined by a 16-point increase in IBDQ score or IBDQ score 170. 18, 19, 21, 29, 30, 32, 36, 39, 41, 46, 47, 56, 60, 61, 64, 66, 69 Other tools for assessing quality of life included the IBD PatientReported Treatment Impact survey 66 , the 36-Item Short Form Survey, 52,60 and the EuroQoL survey.
18
Rectal bleeding and stool frequency, as reported by the patient, were also described as PROs. 37, 48, 52 They have been combined into a 2-item PRO. 60 An alternative composite endoscopic and patient-reported endpoint using mucosal healing, absence of rectal bleeding, and stool frequency <5 bowel motions per day (ClinPRO) has also been proposed.
60
Safety Outcomes and Definitions
Reporting of any AEs (regardless of frequency) occurred in 64 (94.1%) induction 6, 7, [10] [11] [12] [13] [59] [60] [61] [62] [63] [64] [65] [66] [67] [68] [69] and Figure 2 . Proportion of placebo-controlled ulcerative colitis trials reporting key efficacy and safety outcome domains, stratified by decade of publication.
13 (86.7%) maintenance trials 13, 23, 36, 38, 41, 47, 51, 65, [71] [72] [73] [74] (Supplementary Table 7 ). Serious AEs were reported in 57 (83.8%) induction 11, 13, 15, [55] [56] [57] [59] [60] [61] [62] [63] [64] [65] [66] [67] 69 and 12 (80.0%) maintenance trials. 13, 23, 36, 38, 41, 47, 51, 65, 71, 73, 74 Gastrointestinal-related AEs, including worsening of UC, were the most commonly described organ-specific AEs, reported in 55 (80.9%) induction and 11 (73.3%) maintenance trials.
Time to Outcome Assessment
Time to outcome assessment is summarized in Supplementary Tables 4-6. Median time to assessment was 8 weeks (interquartile range, 6-8 weeks) in induction studies and 32 weeks (interquartile range, 24-52 weeks) in maintenance studies. The earliest time to assessment in the induction phase was 2 weeks and the longest time to outcome measurement in maintenance was 96 weeks. Twenty-one studies described multiple time points of assessment.
Discussion
As clinical trial design in UC has evolved, there has been a re-evaluation of the key outcomes that should be measured shifting from symptom-based assessment to objective measures of inflammation. In this systematic review of all placebo-controlled UC trials of major therapeutic classes, we highlight the heterogeneity in definitions of clinical response and remission and demonstrate the progressive adoption of endoscopic outcomes, histologic outcomes, biomarker outcomes, and PROs. By comprehensively appraising the efficacy and safety outcomes reported, we establish a framework by which a COS for UC RCTs can be developed. 4 Clinical response and remission have traditionally been the primary efficacy endpoints in UC RCTs, but over 50 definitions have been used. Comparisons of relative therapeutic efficacy and safety between different therapies are invalid when such significant heterogeneity in outcome definitions exists, further highlighting the need for a COS in UC. In the Selecting Therapeutic Targets for Inflammatory Bowel Disease recommendations, the resolution of rectal bleeding and normalization of stool frequency have been emphasized as treatment targets.
2 Use of a 2-item PRO comprising rectal bleeding and stool frequency rather than the full MCS yields similar treatment effect sizes in post hoc analysis of clinical trial data. 75 As PROs become an increasingly central component of assessing treatment response, standardization of definitions and units of meaningful change will be needed.
3
Endoscopic endpoints are nearly universally reported as an outcome domain in contemporary RCTs. However, the precise definition of mucosal healing remains contentious. Although most RCTs use a MCS subscore cutoff 1, it remains unclear if a stricter definition of mucosal healing by a MCS subscore of 0 is associated with improved long-term outcomes 76 ; these definitions in turn are likely to influence reported efficacy rates. Centralized endoscopy reading, which is a regulatory standard, has been demonstrated to allow enrollment of properly eligible subjects, improve inter-and intrarater variability in endoscopic scoring, 42 and may reduce bias and improve efficiency in trial design.
77 Beyond endoscopic outcomes, histologic endpoints are increasingly described. "Deep remission," defined by mucosal healing with resolution of histologic inflammation, may predict improved long-term outcomes in UC.
78 Furthermore, the Food and Drug Administration is proposing that a claim of mucosal healing will only be granted with the inclusion of histopathologic assessment. 77 However, the lack of fully validated instruments or accepted definitions to measure histologic response or remission in existing scales is a limitation to incorporating histopathologic assessment in UC RCTs.
Measuring endoscopic and histologic outcomes is limited by the requirement for invasive endoscopic procedures. Accordingly, there has been great interest in measuring noninvasive biomarkers as a treatment target. Over one-third of UC RCTs published in the last decade have reported biomarker outcomes, most prominently FCP and C-reactive protein. FCP is a reliable biomarker for mucosal inflammation and predicts loss of response during maintenance therapy. 79 However, its role as a treatment target is yet to be defined. Whether a "treat-totarget" approach guided by biomarker endpoints improves deep remission outcomes in UC is unclear, although promising results in Crohn's disease based on this strategy have recently been reported from the Efficacy and Safety of Two Treatment Models in Subjects With Moderate to Severe Crohn's Disease (CALM) trial. Safety outcomes were reported in nearly 95% of UC RCTs. Accurate reporting of safety outcomes is essential but poses unique challenges. First, the prospective RCT is not the optimal study design for evaluating the safety of new therapies, as rare but serious events are unlikely to be detected. Thus, careful monitoring for AEs in postmarketing studies and prospective treatment registries is required.
81 Second, inadequate ascertainment of AEs is magnified in RCTs when they are defined by spontaneous reporting from trial participants rather than by systematic monitoring and prespecification of safety outcomes. Use of a standardized and validated terminology for AE reporting, such as the Medical Dictionary for Regulatory Activities, may limit misclassification errors.
Studies of antibiotics, probiotics, or complementary therapy were excluded from this review. However, we recognize that these therapies may have an important role in patients with pouchitis and as adjuncts in combination with conventional therapy. Previous studies have evaluated the efficacy and safety of metronidazole, 82 88, 89 Importantly, few of these RCTs were truly placebo controlled. As with trials of conventional therapy, authors have used a variety of definitions of clinical response or remission, primarily defined using composite scores such as the UCDAI. There is a paucity of rigorously conducted studies of complementary therapies that use validated endoscopic or histologic outcomes.
Our study has limitations. First, we included only placebo-controlled RCTs. However, this design is the gold standard for obtaining drug approval and there are few head-to-head active comparator trials. Second, we included only studies using the MCS, UCDAI, or modifications of these indices as inclusion criteria for patient recruitment. The rationale for this criterion was to focus the review on contemporary outcomes relevant to modern day clinical development, and hence the data analysis is restricted to studies published after 1987. Previously used clinical indices have fallen out of favor and are primarily of historical relevance. 90 Finally, we could not account for study publication bias in this review: it is possible that additional outcomes of interest used in negative studies are uncaptured.
The next steps in developing a COS involves prioritization and ratification of outcomes using a Delphi method (Box 1). A full description is outside the scope of this manuscript but has been described elsewhere. 4 The COS development process poses unique challenges. First, the selection of relevant outcomes and definitions for RCTs will be influenced by stakeholder priorities and anticipated future directions in UC research. This review underlines the need to consider integrating histologic outcomes, biomarker outcomes, and PROs. Indeed, several validated indices for endoscopic, histologic, and quality-of-life outcomes now exist for use in clinical practice but have not yet been incorporated in RCTs. Examples include the IBD Control Questionnaire 91 and the Nancy Histological Index. 92 Second, novel scoring and assessment methods should be considered for inclusion in the COS to bridge the gap between RCTs and clinical practice, and to ensure the COS is applicable to future studies. Qualitative interviews with clinicians, researchers, patients, and policymakers will be conducted to identify outcomes of importance not currently captured in the literature.
In conclusion, the last 3 decades have seen a surge in clinical trial research in UC, with multiple novel therapies being evaluated in increasingly complex RCTs. There has been a shift toward the reporting of endoscopic, histologic, biomarker, and patient-reported endpoints in these trials. However, the heterogeneity of outcome definitions as well as the evolving landscape of treatment endpoints in UC highlights the exigent need for an international consensus on core outcomes for use in future UC trials. This is important to facilitate both direct and indirect comparisons of treatment efficacy and to harmonize clinical development. This systematic review provides the conceptual framework for COS development in UC. Multicenter, single country (2) Aminosalicylate (suppository) 27 13 7.4 6 Sutherland 1990
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